BMY – Bristol-Myers Squibb Company
Float Short %
1.49
Margin Of Safety %
31
Put/Call OI Ratio
0.81
EPS Next Q Diff
-0.13
EPS Last/This Y
5.38
EPS This/Next Y
-0.49
Price
46
Target Price
52.6
Analyst Recom
2.62
Performance Q
0.37
Relative Volume
1.41
Beta
0.34
Ticker: BMY
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-10-06 | BMY | 45.12 | 0.87 | 0.54 | 708945 |
| 2025-10-07 | BMY | 44.66 | 0.87 | 0.58 | 738205 |
| 2025-10-08 | BMY | 44.54 | 0.87 | 0.36 | 757895 |
| 2025-10-09 | BMY | 44.68 | 0.86 | 0.18 | 768925 |
| 2025-10-10 | BMY | 43.98 | 0.82 | 0.73 | 793339 |
| 2025-10-13 | BMY | 43.53 | 0.82 | 0.56 | 761415 |
| 2025-10-14 | BMY | 43.81 | 0.82 | 0.28 | 785878 |
| 2025-10-15 | BMY | 43.62 | 0.79 | 0.34 | 802441 |
| 2025-10-16 | BMY | 43.4 | 0.79 | 0.65 | 811784 |
| 2025-10-17 | BMY | 43.62 | 0.78 | 0.23 | 828258 |
| 2025-10-20 | BMY | 43.59 | 0.76 | 0.48 | 738712 |
| 2025-10-21 | BMY | 44.54 | 0.75 | 0.21 | 759502 |
| 2025-10-22 | BMY | 44.39 | 0.72 | 0.51 | 785250 |
| 2025-10-23 | BMY | 43.83 | 0.73 | 0.60 | 797988 |
| 2025-10-24 | BMY | 43.83 | 0.72 | 0.48 | 807985 |
| 2025-10-27 | BMY | 43.38 | 0.76 | 0.65 | 755322 |
| 2025-10-28 | BMY | 42.83 | 0.75 | 0.43 | 800771 |
| 2025-10-29 | BMY | 42.64 | 0.74 | 0.54 | 860643 |
| 2025-10-30 | BMY | 45.63 | 0.74 | 0.51 | 902820 |
| 2025-10-31 | BMY | 46.1 | 0.76 | 0.82 | 931964 |
| 2025-11-03 | BMY | 46.01 | 0.81 | 0.52 | 836256 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-10-06 | BMY | 45.12 | -6.5 | 5528.7 | 6.52 |
| 2025-10-07 | BMY | 44.63 | -6.5 | 5414.2 | 6.52 |
| 2025-10-08 | BMY | 44.55 | -6.5 | 5501.7 | 6.52 |
| 2025-10-09 | BMY | 44.68 | -6.5 | 5557.9 | 6.52 |
| 2025-10-10 | BMY | 43.96 | -8.5 | 5365.3 | 6.52 |
| 2025-10-13 | BMY | 43.53 | -8.5 | 5429.1 | 6.50 |
| 2025-10-14 | BMY | 43.81 | -9.6 | 5587.9 | 6.48 |
| 2025-10-15 | BMY | 43.61 | -11.4 | 5483.4 | 6.46 |
| 2025-10-16 | BMY | 43.39 | -11.9 | 5476.4 | 6.44 |
| 2025-10-17 | BMY | 43.63 | -11.9 | 5581.2 | 6.44 |
| 2025-10-20 | BMY | 43.60 | -12.4 | 5519.6 | 6.43 |
| 2025-10-21 | BMY | 44.53 | -12.8 | 5740.5 | 6.42 |
| 2025-10-22 | BMY | 44.39 | -13.7 | 5492.9 | 6.41 |
| 2025-10-23 | BMY | 43.82 | -13.7 | 5398.2 | 6.41 |
| 2025-10-24 | BMY | 43.84 | -14.3 | 5528.7 | 6.39 |
| 2025-10-27 | BMY | 43.38 | -14.3 | 5424.3 | 6.39 |
| 2025-10-28 | BMY | 42.82 | -14.3 | 5396.1 | 6.39 |
| 2025-10-29 | BMY | 42.64 | -14.3 | 5484.9 | 6.39 |
| 2025-10-30 | BMY | 45.62 | -15.8 | 6300.7 | 6.36 |
| 2025-10-31 | BMY | 46.07 | -15.8 | 5698.0 | 6.36 |
| 2025-11-03 | BMY | 46.00 | -2.6 | 4169.7 | 6.53 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-10-06 | BMY | -4.10 | 0.61 | 1.45 |
| 2025-10-07 | BMY | -4.10 | 0.61 | 1.45 |
| 2025-10-08 | BMY | -4.10 | 0.61 | 1.45 |
| 2025-10-09 | BMY | -4.10 | 0.61 | 1.45 |
| 2025-10-10 | BMY | -4.10 | 0.61 | 1.29 |
| 2025-10-13 | BMY | -4.10 | 0.65 | 1.29 |
| 2025-10-14 | BMY | -4.10 | 0.65 | 1.29 |
| 2025-10-16 | BMY | -4.10 | 0.65 | 1.29 |
| 2025-10-17 | BMY | -4.10 | 0.65 | 1.29 |
| 2025-10-20 | BMY | -4.10 | 0.03 | 1.29 |
| 2025-10-21 | BMY | -4.10 | 0.03 | 1.29 |
| 2025-10-22 | BMY | -4.10 | 0.03 | 1.29 |
| 2025-10-23 | BMY | -4.10 | 0.03 | 1.29 |
| 2025-10-24 | BMY | -4.10 | 0.03 | 1.29 |
| 2025-10-27 | BMY | -4.10 | 0.55 | 1.49 |
| 2025-10-28 | BMY | -4.10 | 0.55 | 1.49 |
| 2025-10-29 | BMY | -4.10 | 0.55 | 1.49 |
| 2025-10-30 | BMY | -4.42 | 0.55 | 1.49 |
| 2025-10-31 | BMY | -4.42 | 0.55 | 1.49 |
| 2025-11-03 | BMY | -4.42 | 0.65 | 1.49 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
1.63
Avg. EPS Est. Current Quarter
1.63
Avg. EPS Est. Next Quarter
1.5
Insider Transactions
-4.42
Institutional Transactions
0.65
Beta
0.34
Average Sales Estimate Current Quarter
12092
Average Sales Estimate Next Quarter
10417
Fair Value
60.16
Quality Score
83
Growth Score
49
Sentiment Score
95
Actual DrawDown %
43.5
Max Drawdown 5-Year %
-47.7
Target Price
52.6
P/E
15.54
Forward P/E
7.64
PEG
0.22
P/S
1.95
P/B
5.05
P/Free Cash Flow
6.12
EPS
2.96
Average EPS Est. Cur. Y
6.53
EPS Next Y. (Est.)
6.04
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
12.57
Relative Volume
1.41
Return on Equity vs Sector %
6.8
Return on Equity vs Industry %
-3.9
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
0.01
EBIT Estimation
4169.7
Bristol-Myers Squibb CompanySector: Healthcare
Industry: Drug Manufacturers - General
Employees: 34100
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
stock quote shares BMY – Bristol-Myers Squibb Company Stock Price stock today
news today BMY – Bristol-Myers Squibb Company stock forecast ,stock prediction 2023 2024 2025
marketwatch BMY – Bristol-Myers Squibb Company yahoo finance google finance
stock history BMY – Bristol-Myers Squibb Company invest stock market
stock prices BMY premarket after hours
ticker BMY fair value insiders trading